Pinetree Therapeutics Closes $17 Million in Series A Funding to Advance AbReptor™ Protein Degradation Platform and Portfolio Programs
|
Pinetree Therapeutics Announces Exclusive Option and Global License Agreement for Preclinical EGFR Degrader Candidate with AstraZeneca
|
PineTree Therapeutics Receives a Bits and Bytes Grant from Massachusetts Life Sciences Center
|
PineTree Therapeutics, Inc. Secures $23.5 Million of Series A1 Funding to Develop Cutting Edge Platform Technology to Create Therapeutic Assets for Unmet Medical Needs
|
Pinetree Therapeutics
West Cambridge Scientific Park
767C Concord Ave
Cambridge MA 02138
Website designed by Creative Eye Design
West Cambridge Scientific Park
767C Concord Ave
Cambridge MA 02138
Website designed by Creative Eye Design